search
Back to results

CoolSculpting System (ELI)

Primary Purpose

Body Fat Disorder

Status
Unknown status
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
The ZELTIQ System
Sponsored by
Zeltiq Aesthetics
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Body Fat Disorder

Eligibility Criteria

22 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria

  • Subject (healthy volunteer) has read and signed the study written informed consent form.
  • Male or female ≥ 22 years and ≤65 years of age.
  • Subject has clearly visible fat in one or more areas on the torso (abdomen, flank, back fat, bra fat), which in the investigator's opinion, may benefit from the treatment.
  • Subject has not had weight change exceeding 5% of body weight in the preceding month.
  • Subject agrees to maintain his/her weight (i.e., within 5%) by not making any major changes in their diet or exercise routine during the study.
  • Subject has a BMI ≤ 30 as determined at screening.
  • Subject agrees to have photographs taken of the treatment area(s) during the scheduled time periods.

Exclusion Criteria

  • Subject has had a recent surgical procedure in the area of intended treatment.
  • Subject has had an invasive fat reduction procedure (e.g., liposuction, mesotherapy) in the area of intended treatment.
  • Subject has had a non-invasive fat reduction and/or body contouring procedure in the area of intended treatment within the past 12 months.
  • Subject needs to administer or has a known history of subcutaneous injections into the area of intended treatment (e.g., heparin, insulin) within the past month.
  • Subject has a known history of cryoglobulinemia, paroxysmal cold hemoglobinuria, or cold agglutinin disease.
  • Subject has a known sensitivity to cold, such as cold urticaria, Raynaud's disease, chilblains (pernio), or any known condition with a response to cold exposure that limits blood flow to the skin.
  • Subject has a history of bleeding disorder or is taking any medication that in the investigator's opinion may increase the subject's risk of bruising.
  • Subject is taking or has taken diet pills or supplements within the past month.
  • Subject has any dermatological conditions, such as moderate to excessive skin laxity, or scars in the location of the treatment sites that may interfere with the treatment or evaluation (stretch marks is not an exclusion).
  • Subject has an active implanted device such as a pacemaker, defibrillator, or drug delivery system
  • Subject has a history of hernia in the area(s) to be treated.
  • Subject is pregnant or intending to become pregnant during the study period (in the next 8 months).
  • Subject is lactating or has been lactating in the past 6 months.
  • Subject is unable or unwilling to comply with the study requirements.
  • Subject is currently enrolled in a clinical study of any unapproved investigational drug or device.
  • Any other condition or laboratory value that would, in the professional opinion of the investigator, potentially affect the subject's response or the integrity of the data or would pose an unacceptable risk to the subject.

Sites / Locations

  • Marina Plastic Surgery
  • Riverchase Dermatology

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Fat Reduction

Arm Description

The treatments are designed to see if the fat can be reduced in the torso area with a new applicator design.

Outcomes

Primary Outcome Measures

Efficacy Endpoint: Independent Photo Review
Correct identification of pre-treatment vs. 12-week post-treatment images by at least two out of three blinded, independent reviewers. Success will be defined as at least 70% correct identification of the pre-treatment images.

Secondary Outcome Measures

Safety Endpoint: AE's
The frequency of device and procedure-related adverse events (AEs), including device-related serious adverse events (SADEs), will be summarized.

Full Information

First Posted
August 6, 2020
Last Updated
August 6, 2020
Sponsor
Zeltiq Aesthetics
search

1. Study Identification

Unique Protocol Identification Number
NCT04506307
Brief Title
CoolSculpting System
Acronym
ELI
Official Title
Noninvasive Fat Reduction With the CoolSculpting System
Study Type
Interventional

2. Study Status

Record Verification Date
July 2020
Overall Recruitment Status
Unknown status
Study Start Date
March 13, 2020 (Actual)
Primary Completion Date
June 2021 (Anticipated)
Study Completion Date
December 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Zeltiq Aesthetics

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Evaluate the safety and efficacy of multiple, simultaneous CoolSculpting cycles for the purpose of non-invasive fat reduction.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Body Fat Disorder

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Fat Reduction
Arm Type
Experimental
Arm Description
The treatments are designed to see if the fat can be reduced in the torso area with a new applicator design.
Intervention Type
Device
Intervention Name(s)
The ZELTIQ System
Intervention Description
The CoolSculpting machine will be used to perform the treatments.
Primary Outcome Measure Information:
Title
Efficacy Endpoint: Independent Photo Review
Description
Correct identification of pre-treatment vs. 12-week post-treatment images by at least two out of three blinded, independent reviewers. Success will be defined as at least 70% correct identification of the pre-treatment images.
Time Frame
one-month post final data collection
Secondary Outcome Measure Information:
Title
Safety Endpoint: AE's
Description
The frequency of device and procedure-related adverse events (AEs), including device-related serious adverse events (SADEs), will be summarized.
Time Frame
one-month post final data collection

10. Eligibility

Sex
All
Minimum Age & Unit of Time
22 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria Subject (healthy volunteer) has read and signed the study written informed consent form. Male or female ≥ 22 years and ≤65 years of age. Subject has clearly visible fat in one or more areas on the torso (abdomen, flank, back fat, bra fat), which in the investigator's opinion, may benefit from the treatment. Subject has not had weight change exceeding 5% of body weight in the preceding month. Subject agrees to maintain his/her weight (i.e., within 5%) by not making any major changes in their diet or exercise routine during the study. Subject has a BMI ≤ 30 as determined at screening. Subject agrees to have photographs taken of the treatment area(s) during the scheduled time periods. Exclusion Criteria Subject has had a recent surgical procedure in the area of intended treatment. Subject has had an invasive fat reduction procedure (e.g., liposuction, mesotherapy) in the area of intended treatment. Subject has had a non-invasive fat reduction and/or body contouring procedure in the area of intended treatment within the past 12 months. Subject needs to administer or has a known history of subcutaneous injections into the area of intended treatment (e.g., heparin, insulin) within the past month. Subject has a known history of cryoglobulinemia, paroxysmal cold hemoglobinuria, or cold agglutinin disease. Subject has a known sensitivity to cold, such as cold urticaria, Raynaud's disease, chilblains (pernio), or any known condition with a response to cold exposure that limits blood flow to the skin. Subject has a history of bleeding disorder or is taking any medication that in the investigator's opinion may increase the subject's risk of bruising. Subject is taking or has taken diet pills or supplements within the past month. Subject has any dermatological conditions, such as moderate to excessive skin laxity, or scars in the location of the treatment sites that may interfere with the treatment or evaluation (stretch marks is not an exclusion). Subject has an active implanted device such as a pacemaker, defibrillator, or drug delivery system Subject has a history of hernia in the area(s) to be treated. Subject is pregnant or intending to become pregnant during the study period (in the next 8 months). Subject is lactating or has been lactating in the past 6 months. Subject is unable or unwilling to comply with the study requirements. Subject is currently enrolled in a clinical study of any unapproved investigational drug or device. Any other condition or laboratory value that would, in the professional opinion of the investigator, potentially affect the subject's response or the integrity of the data or would pose an unacceptable risk to the subject.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kerrie Jiang, NP
Organizational Affiliation
Zeltiq Aesthetics
Official's Role
Study Director
Facility Information:
Facility Name
Marina Plastic Surgery
City
Marina Del Rey
State/Province
California
ZIP/Postal Code
90292
Country
United States
Facility Name
Riverchase Dermatology
City
Miami
State/Province
Florida
ZIP/Postal Code
33133
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

CoolSculpting System

We'll reach out to this number within 24 hrs